Company news
Niox Group Plc (LSE:NIOX) news
Niox Group Plc news releases on 6ix. Latest, Mar 27, 2023: Annual Report
Press releases — page 2
Annual Report
March 27, 2023
Preliminary Results
March 21, 2023
Trading Statement
January 17, 2023
Confirmation of Capital Reduction
November 8, 2022
NIOX : Interim Report & Accounts 2022
November 3, 2022
NIOX : Interim Results 2022 Presentation
October 13, 2022
Result of GM and Proposed Capital Reduction
October 6, 2022
Replacement: Block listing Cancellation and Review
September 30, 2022
Interim Results - Ended 30 June 2022
September 14, 2022
Proposed Capital Reduction Scheme and Notice of GM
September 13, 2022
Change of Company Name
September 1, 2022
Proposed Change of Name and Notice of GM
August 11, 2022
Change of Auditor
July 21, 2022
Update regarding Beyond Air product approval
June 29, 2022
Extension of Block Admission
May 27, 2022
Second Price Monitoring Extn
May 25, 2022
Annual Report and Notice of AGM
April 13, 2022
Interim Results - Ended 30 June 2021
September 16, 2021
First Half Trading Update
July 13, 2021
Settlement Agreement reached with Beyond Air
May 26, 2021
Subscription to raise £5 million
March 24, 2021
PDMR Dealing - Transfer for Nil Consideration
February 4, 2021
Change of Nominated Adviser and Broker
January 12, 2021
Board Appointment
November 13, 2020
Interim Results - Ended 30 June 2020
September 17, 2020
Annual report and notice of AGM
June 17, 2020
Equity Financing Facility
June 2, 2020
Completion of Transaction
May 28, 2020
Further re Transfer of Assets
May 27, 2020
Change of Name Effective
May 1, 2020
Issue of Equity
April 27, 2020
Posting of circular and update on undertakings
April 15, 2020
Proposed transfer of assets
April 9, 2020
Further re Board appointment
February 28, 2020
Circassia Announces Business Update
January 9, 2020
Update on Licensing Agreement with BeyondAir Inc.
December 19, 2019
Circassia Announces Board Changes
December 5, 2019
US launch of Duaklir at CHEST 2019
October 21, 2019
Interim Results for Six Months Ended 30 June 2019
September 26, 2019
Notice of Results and Appointment of Joint Broker
September 12, 2019
Appointment of Jonathan Emms as COO
August 12, 2019
Price Monitoring Extension
June 17, 2019
Publication of Tudorza Phase IV ASCENT in JAMA
May 8, 2019
FDA approval of Duaklir for treatment of COPD
April 1, 2019
FDA website posts Duaklir NDA approval
March 29, 2019
Notice of Results
February 8, 2019
Successful FDA Presubmission Meeting for AirNOvent
February 4, 2019
Commercial rights acquired from AIT Therapeutics
January 24, 2019
General Meeting Business Update
January 4, 2019
Listing Rule 9.6.14(R) Disclosure
December 17, 2018